{"search_session":{},"preferences":{"l":"es","queryLanguage":"es"},"patentId":"030-437-480-170-316","frontPageModel":{"patentViewModel":{"ref":{"entityRefType":"PATENT","entityRefId":"030-437-480-170-316"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":8761,"type":"PATENT","title":"University of Chicago","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":5987,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8204,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Searched applicants and Owners= \"Chicago Univ \", \"Univ Chicago\", \"\"Chicago University \" NOT \"loyola\"\", \" \"Univ Chic* NOT \"Loyola\" \".
Select more for logical variants
Add to collection
Select the result in the collection and expand by simple families
Add to collection
Total patents: 4656
Searched applicants and Owners= \"Chicago Univ \", \"Univ Chicago\", \"\"Chicago University \" NOT \"loyola\"\", \" \"Univ Chic* NOT \"Loyola\" \".
Select more for logical variants
Add to collection
Select the result in the collection and expand by simple families
Add to collection
Total patents: 4656
obtaining a nucleic acid sample from the patient; and\n
determining from the sample the nucleotide sequence at position −3156 in one or both UGT1A1 genes of the patient, wherein determination of an adenine residue at position −3156 in one or both UGT1A1 genes indicates the patient is at risk for irinotecan toxicity."],"number":1,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, further comprising classifying the UGT1A1 activity level in the patient, whereby identification of a guanine residue indicates the patient does not have a low level of activity."],"number":2,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the nucleotide sequence at position −3156 is determined for one UGT1A1 gene."],"number":3,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the nucleotide sequence at position −3156 is determined for both UGT1A1 genes in the patient."],"number":4,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, further comprising analyzing a glucuronidation rate associated with a sequence at position −3156 in one or both UGT1A1 genes."],"number":5,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, further comprising optimizing a dose of irinotecan for administration to the patient."],"number":6,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 1, wherein determining the sequence at position −3156 in one or both UGT1A1 genes is performed by a hybridization assay."],"number":7,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 1, wherein determining the nucleotide sequence at position −3156 of a UGT1A1 gene or genes is performed by a sequencing or microsequencing assay."],"number":8,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 1, wherein determining the nucleotide sequence at position −3156 of a UGT1A1 gene or genes is performed by an allele-specific amplification assay."],"number":9,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, further comprising administering to the patient irinotecan."],"number":10,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 10, further comprising administering to the patient a second agent to reduce excretion of an active irinotecan species through the bile."],"number":11,"annotation":false,"title":false,"claim":true},{"lines":["A method for evaluating the risk of irinotecan toxicity in a cancer patient being considered for irinotecan therapy comprising:\n
obtaining a nucleic acid sample from the patient; and,\n
sequencing the sample to determine the nucleotide sequence at position −3156 in one or both UGT1A1 genes of the patient, wherein identification of an adenine residue at position −3156 in one or both UGT1A1 genes indicates the patient is at risk for irinotecan toxicity."],"number":12,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 12, further comprising classifying the UGT1A1 activity level in the patient, whereby identification of a guanine residue indicates the patient does not have a low level of activity."],"number":13,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 12, further comprising administering irinotecan to the patient if a guanine nucleotide is found at position −3156."],"number":14,"annotation":false,"title":false,"claim":true}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}